Replies to post #366325 on Anavex Life Sciences Corp (AVXL)

[Rubyred77]

Yet for some reason, here we are in the 12s.

What an amazing opportunity retail investors have.

[Investor2014]

I will assume and expect your prose it meant to express that P-values of < 0.05 and clinical meaningfulness unfortunately are not synonymous.

So, what if all of the P-values are <0.05? Simply, then, blarcamesine works; is a viable, useful Alzheimer’s disease therapeutic. No more questions, other than when and how can Alzheimer’s patients start their Anavex therapies?

Pretty sure the Donepezil trials had P-values of <0.05 and as I hear it, not least here, Donepezil doesn't work as a useful Alzheimer’s disease therapeutic.

Biogen managed to post hoc analyse their way to show the right P-values and some expression of therapeutic benefits outweighing risks. The medical practitioners, insurance companies and the European Medicines Agency didn't agree.

Fortunately, and we shall see how the FDA behaves going forward, there is a shift towards making sure safety and clinical meaningfulness weighs in as the big brother alongside P-values. Both are needed!